Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.

6582 Background: Prior real-world (RW) studies of advanced non-small cell lung cancer (adv NSCLC) have described overall survival (OS) from diagnosis (Dx) for all patients (pts) as well as separately by whether chemotherapy was received. More recently, innovations in systemic anti-cancer treatment (SATx) have expanded to include oral targeted agents. Current RW data on OS of advanced pts in the US are limited, particularly by line of therapy (LOT). In this study, we use data from a recent cohort of SEER-Medicare pts to examine OS from adv NSCLC Dx for all pts and separately by SATx status. For treated pts, we also describe OS from initiation of each LOT. Methods: Fee-for-service pts aged ≥66 enrolled in Medicare Parts A/B/D with an incident Dx of adv NSCLC (Stage IIIB/IV) during 2007–9 were identified in the SEER-Medicare linked database. OS follow-up was available through 12/31/2011. We examined demographic and clinical characteristics, including histology, and the receipt of SATx (chemotherapy, tyrosine...